EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program

All NewsMay 7, 2025

Alzamend Neuro teams up with QMENTA for five AL001 Phase 2 trials at Mass General, targeting Alzheimer’s, PTSD, bipolar disorder, and more.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent